# A Study to Evaluate the Efficacy and Safety of JKB-122 in Patients With NASH and Fibrosis

> **NCT04255069** · PHASE2 · UNKNOWN · sponsor: **TaiwanJ Pharmaceuticals Co., Ltd** · enrollment: 300 (estimated)

## Conditions studied

- Nonalcoholic Steatohepatitis (NASH) With Fibrosis

## Interventions

- **DRUG:** Placebo
- **DRUG:** Dose 1 JKB-122
- **DRUG:** Dose 2 JKB-122

## Key facts

- **NCT ID:** NCT04255069
- **Lead sponsor:** TaiwanJ Pharmaceuticals Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-06-30
- **Primary completion:** 2023-06-30
- **Final completion:** 2023-12-31
- **Target enrollment:** 300 (ESTIMATED)
- **Last updated:** 2020-02-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04255069

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04255069, "A Study to Evaluate the Efficacy and Safety of JKB-122 in Patients With NASH and Fibrosis". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04255069. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*